In 2023,the global diagnostic ECG market was valued at USD 6124 million and it is expected to reach USD 10487.79 million by 2032 from USD 6501.24 million in 2024, growing at a CAGR of 6.16 % during the forecast period.
The growing incidence of CVDs such as ischemic heart disease (IHD), hypertensive heart disease, stroke, and peripheral artery diseases propel the diagnostic ECG market growth. According to the statistics published by World Health Organization (WHO), CVDs are one of the leading causes of death worldwide and caused 17.9 million deaths worldwide in 2023. The growing number of deaths and an increasing number of people suffering from cardiovascular diseases are promoting the need for diagnostic ECG devices. These diseases majorly occur due to the increasing prevalence of unhealthy lifestyles. However, awareness regarding the negative impact of an unhealthy lifestyle is deficient among the public.
In addition, the growing aging population, increasing improvements in the healthcare infrastructure in developing and underdeveloped countries, and the availability of reimbursement policies are anticipated to showcase a favorable impact on the diagnostic ECG market growth. Developing nations witness high growth opportunities compared to developed countries because the market of developed nations is almost saturated. In addition, developing economies have an environment of favorable government policies and growing healthcare spending, which are estimated to favor market growth.
Furthermore, the rise in the support from government organizations through investments to minimize the cost of treatment procedures in healthcare centers is lavishing the need for the diagnostic ECG market. Technological advancements in communication, low-power circuit design for safer ECG devices, portability features, lower power consumption, more accuracy, and the capacity to incorporate the latest diagnostic features support market growth. The rising aging population worldwide and increasing incidence of lifestyle diseases are contributing to the growth of the global diagnostic ECG market. In addition, a growing tendency for early diagnosis of a disease by knowing the benefits involved in detecting the disease at an early stage is escalating market growth.
However, unstable reimbursement regulations, the high cost of devices, and economic instability are the major factors hindering the growth of the diagnostic ECG market.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2032 |
Base Year |
2023 |
Forecast Period |
2024 to 2032 |
Segments Covered |
By Product, Lead Type, End User, and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
Market Leaders Profiled |
BPL Ltd, Cardiac Science Corp, Fukuda Denshi Co., Ltd., GE Healthcare, Medtronic, Inc., Philips Healthcare, Spacelabs, Healthcare, Inc., Mortara Instrument, Midmark Corp, Mindray Medical International Ltd., Nihon Kohden Corp, Scottcare Corp, Schiller Ag, Welch Allyn Inc., and Cardionet |
Based on the product, the resting ECG systems segment had the major share of the worldwide diagnostic ECG market in 2023 and is estimated to grow at a healthy CAGR during the forecast period.
On the other hand, the stress ECG systems segment is anticipated to grow at a healthy CAGR during the forecast period owing to the growing incidence of stress levels, especially among the young population across the world, propelling the segment's growth. In addition, the growing consistency of patient visits to the hospital is fuelling the segment’s growth.
Based on the lead type, the 3-6 lead type ECG devices segment is forecasted to lead the diagnostic ECG market during the forecast period. The growing adoption of technological developments is one of the significant factors propelling segmental growth. In addition, favorable reimbursement policy environments in multiple countries and increasing government support promote the segment's growth.
Based on the end-user, the hospital segment accounted for the major share of the worldwide diagnostic ECG market in 2023. The segment’s dominance is anticipated to continue during the forecast period. The growing number of hospitals worldwide and the increasing number of patients worldwide contribute to the segment’s growth. In addition, the rising implementation of portable devices in ambulatory services is another factor for the market to grow. It can save many people suffering from cardiac arrest before reaching the hospital.
The North American diagnostic electrocardiograph (ECG) market accounted for the major share of the worldwide market in 2023and is anticipated to continue dominating throughout the forecast period. The growing adoption of technological developments and increasing incidence of cardiovascular diseases propel the region’s growth. In addition, the demand for diagnostic ECG devices is anticipated to grow in the coming days due to the increasing usage of these devices from hospitals, diagnostic centers, and in-home care settings. The U.S. led the diagnostics ECG market in 2023, followed by Canada. The domination of the U.S. market in the North American region is majorly attributed to the consistent growth in the patient volume; increasing patient count suffering from CVDs, and the availability of well-advanced healthcare infrastructure.
The European diagnostic ECG market is anticipated to hold a considerable share of the worldwide market during the forecast period. The European region is considered one of the potential regions in the worldwide market and is expected to grow at a healthy CAGR in the coming years. The growing aging population, increasing adoption of technological developments to manufacture portable and wireless ECG devices, rising incidence of chronic diseases, and growing initiatives from EU governments to develop the healthcare infrastructure are contributing to the growth of the European market. In addition, the growing R&D activities by companies such as GE Healthcare, Philips Healthcare, Schiller AG, and Welch Allyn are expected to favor regional market growth.
The Asia Pacific diagnostic ECG market is predicted to grow at the fastest CAGR in the coming years owing to the growing patient population and increasing support from the governments of the APAC countries in terms of launching reimbursement schemes in favor of the public. The growing healthcare spending and increasing government support are propelling the regional market growth. Countries like India and China are anticipated to hold a major share of the APAC diagnostic ECG market during the forecast period.
The Latin American diagnostic ECG market is expected to showcase a steady CAGR during the forecast period.
The diagnostic ECG market in MEA is forecasted to hold a moderate share of the worldwide market during the forecast period.
Key players operating in the Global Diagnostic ECG Market profiled in this report are BPL Ltd, Cardiac Science Corp, Fukuda Denshi Co., Ltd, GE Healthcare, Medtronic, Inc., Philips Healthcare, Spacelabs, Healthcare, Inc., Mortara Instrument, Midmark Corp, Mindray Medical International Ltd, Nihon Kohden Corp, Scottcare Corp, Schiller Ag, Welch Allyn Inc., and Cardionet.
In May 2019, Royal Philips and Medtronic announced a collaboration to advance further the treatment of paroxysmal atrial fibrillation (PAF).
In March 2019, BioTelemetry, a leading remote medical technology company, announced that it completed its acquisition of Geneva Healthcare, Inc., the leading provider of remote monitoring for cardiac implantable devices.
This research report on the global diagnostic ECG market has been segmented and sub-segmented based on the Product, Lead Type, End-User, and Region.
By Product
Resting ECG Systems
Stress ECG Systems
By Lead Type
Single-Lead Type ECG Devices
3–6 Lead Type ECG Devices
By End-user
Hospitals
Rehabilitation Centers
By Region
Frequently Asked Questions
The global diagnostic ECG market size was valued at USD 6124.01 million in 2023.
Yes, we have studied and included the COVID-19 impact on the global diagnostic ecg market in this report.
North America is anticipated to play the leading share of the worldwide diagnostic ECG market in the coming years.
BPL Ltd, Cardiac Science Corp, Fukuda Denshi Co., Ltd, GE Healthcare, Medtronic, Inc., Philips Healthcare, Spacelabs, Healthcare, Inc., Mortara Instrument, Midmark Corp, Mindray Medical International Ltd, Nihon Kohden Corp, Scottcare Corp, Schiller Ag, Welch Allyn Inc., and Cardionet are some of the notable companies in the worldwide diagnostic ECG market.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region